WITNESSETH:Employment Agreement • December 19th, 2000 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • New York
INDENTUREIndenture • December 2nd, 2003 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • New York
Portions of this Exhibit 10.35 have been redacted and are the subject of a confidential treatment request filed with the Secretary of the Securities and Exchange Commission. CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT THIS AGREEMENT, dated this...Purchase Agreement • April 9th, 1998 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • Delaware
amongAgreement and Plan of Merger • February 11th, 2003 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • Delaware
Portions of Exhibit 10.2 have been redacted and are the subject of a confidential treatment request filed with the Secretary of the Securities and Exchange Commission. 2 ANADERM RESEARCH CORP. Amended and Restated Stockholders' Agreement dated April...Stockholders' Agreement • August 16th, 1999 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • New York
ASSET PURCHASE AGREEMENT REGARDING THE P93/01 PROGRAM AND ASSETS AND CONTRACTS RELATED THERETOAsset Purchase Agreement • July 6th, 2004 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances
ARTICLE 1 DEFINITIONSLicense Agreement • March 16th, 2006 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • Delaware
3 4 3. VALIDITY AND RESERVATION OF WARRANT SHARESOsi Pharmaceuticals Inc • December 29th, 1997 • In vitro & in vivo diagnostic substances • Delaware
betweenAsset Purchase Agreement • August 16th, 1999 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • New York
RECITALSStock Purchase Agreement • February 14th, 2001 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • Delaware
Amended and Restated May 31, 2005Osi Pharmaceuticals Inc • August 9th, 2005 • In vitro & in vivo diagnostic substances • New York
If the registration statement relating to the Shares has been declared effective under the Act by the Commission, the Company will prepare and promptly file with the Commission the information omitted from the registration statement pursuant to Rule...Oncogene Science Inc • February 14th, 1996 • In vitro & in vivo diagnostic substances • California
AGREEMENTAgreement • June 20th, 2000 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • New York
RECITALSSupply Agreement • May 10th, 2005 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • New York
WITNESSETH:Employment Agreement • August 14th, 1998 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • New York
RECITALSOsi Pharmaceuticals Inc • August 14th, 1998 • In vitro & in vivo diagnostic substances • New York
AGREEMENTOsi Pharmaceuticals Inc • May 17th, 1999 • In vitro & in vivo diagnostic substances • New York
1 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT ("Agreement") dated as of October 1, 1998, is made and entered into by and between OSI PHARMACEUTICALS, INC., a Delaware corporation (the "Company"), and GARY E. FRASHIER (the "Consultant"). W I T N E S...Consulting Agreement • February 12th, 1999 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • New York
1 EXHIBIT 1 UNDERWRITING AGREEMENT [October __, 2000] Robertson Stephens, Inc. Lehman Brothers Inc. Prudential Securities Incorporated Lazard Freres & Co. LLC Adams, Harkness & Hill, Inc. As Representatives of the several Underwriters c/o FleetBoston...Underwriting Agreement • September 29th, 2000 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • New York
1 Portions of this Exhibit 10.35 have been redacted and are the subject of a confidential treatment request filed with the Secretary of the Securities and Exchange Commission. 2 CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT THIS AGREEMENT, dated this...Purchase Agreement • December 29th, 1997 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • Delaware
EXHIBIT 10.4 [OSI PHARMACEUTICALS LETTERHEAD] ADDENDUM TO EMPLOYMENT OFFER FOR BARBARA WOOD CHANGE OF CONTROL AGREEMENT This Agreement dated, October 4, 2001, between OSI Pharmaceuticals and Barbara Wood: In the event OSI is sold or merged with...Change of Control Agreement • May 10th, 2005 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances
1 EXHIBIT 10.1 Portions of Exhibit 10.1 have been redacted and are the subject of a confidential treatment request filed with the Secretary of the Securities and Exchange Commission. LICENSE AGREEMENT AGREEMENT made this 3rd day of January, 2000 (the...License Agreement • June 19th, 2000 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • New York
May 16, 2003 Mr. Gabe Leung 125 Top of the Way World Green Brook, NJ 08812 Re: Employment Agreement Dear Gabe: This letter is to confirm our understanding with respect to (i) your future employment by OSI Pharmaceuticals, Inc. (the "Company"), (ii)...Osi Pharmaceuticals Inc • December 2nd, 2003 • In vitro & in vivo diagnostic substances • New York
EXHIBIT 4.11Registration Rights Agreement • December 2nd, 2003 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • New York
EXHIBIT 4.4Registration Rights Agreement • April 19th, 2002 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • New York
RECITALSInvestor Rights Agreement • January 7th, 2002 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • Colorado
EXHIBIT 1.1 OSI PHARMACEUTICALS, INC. (A DELAWARE CORPORATION) [-] SHARES OF COMMON STOCK PURCHASE AGREEMENT Dated: [-], 2004Purchase Agreement • September 23rd, 2004 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • New York
i 3 RIGHTS AGREEMENTRights Agreement • January 8th, 1999 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • New York
EXHIBIT 10.52 CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS. COLLABORATION AGREEMENTCollaboration Agreement • March 16th, 2006 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • New York
Portions of this Exhibit 10.2 have been redacted and are the subject of a confidential treatment request filed with the Secretary of the Securities and Exchange Commission. COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BETWEEN:...Oncogene Science Inc • February 14th, 1997 • In vitro & in vivo diagnostic substances • New York
Exhibit 10.1 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT ("Agreement") dated as of October 1, 1996, is made and entered into by and between ONCOGENE SCIENCE, INC., a Delaware corporation (the "Company"), and EDWIN A. GEE, PH.D. (the "Consultant")....Consulting Agreement • January 27th, 2005 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • New York
3- 4 payment is to be made by PFIZER and (b) deducting therefrom the amount of any tax, duty, charge, commission, discount or other fee payable in respect of such conversion into, and remittance of, U.S. Dollars; provided, that in the event any...Royalty Agreement • December 20th, 1995 • Oncogene Science Inc • In vitro & in vivo diagnostic substances
1 Portions of this Exhibit 10.3 have been redacted and are the subject of a confidential treatment request filed with the Secretary of the Securities and Exchange Commission. 2 RESEARCH COLLABORATION AND LICENSE AGREEMENT This RESEARCH COLLABORATION...Collaboration and License Agreement • August 14th, 1998 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • New York
RECITALSLicensing Agreement • March 16th, 2006 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • California
EXHIBIT 10.2 AGREEMENT OF SALE AND PURCHASEAgreement of Sale and Purchase • May 10th, 2005 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • New York
